Windtree Therapeutics Stock Investor Sentiment

WINT Stock  USD 0.50  0.01  1.96%   
Slightly above 66% of Windtree Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Windtree Therapeutics suggests that many traders are alarmed. Windtree Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Windtree Therapeutics' earnings reports, geopolitical events, and overall market trends.
  

Windtree Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Windtree Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
3 days ago at prnewswire.com         
WINT Water Intelligence and Polygon enter partnership to deliver enhanced water damage prevention
prnewswire News
few days ago at bizjournals.com         
Windtree Therapeutics CEO to retire with companys future in doubt
bizjournals News
six days ago at www.macroaxis.com         
Acquisition by Craig Fraser of 500 shares of Windtree Therapeutics at 2.4587 subject to Rule 16b-3
Macroaxis News
over a week ago at gurufocus.com         
ARMISTICE CAPITAL, LLC Acquires New Stake in Windtree Therapeutics Inc
Gurufocus Stories at Macroaxis
over a week ago at seekingalpha.com         
Windtree Therapeutics appoints new CEO
seekingalpha News
over a week ago at finance.yahoo.com         
WINT Patient Enrollment in SEISMiC C Trial Starts, Patent Position Expands
Yahoo News
over a week ago at thelincolnianonline.com         
Short Interest in Windtree Therapeutics, Inc. Grows By 301.8
news
over three weeks ago at globenewswire.com         
Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for ...
Macroaxis News: globenewswire.com
over three weeks ago at prnewswire.com         
WINT urges construction industry to tighten up water management processes amid UK JCoP regulation
prnewswire News
over three weeks ago at thelincolnianonline.com         
Windtree Therapeutics, Inc. Short Interest Update
news
over a month ago at news.google.com         
Windtree Therapeutics completes national phase filings for istaroxime - Yahoo Finance
Google News at Macroaxis
over a month ago at www.macroaxis.com         
Disposition of 249004 shares by Bioengine Capital Inc. of Windtree Therapeutics at 12.15 subject to ...
Macroaxis News
over a month ago at finance.yahoo.com         
WINT Lead Drug Candidates, Multiple Programs, Several Upcoming Expected Milestones
Yahoo News
over a month ago at investing.com         
Windtree Therapeutics CEO buys 4.9k in company stock
Investing News at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Craig Fraser of 5431 shares of Windtree Therapeutics at 0.9099 subject to Rule 16b-3
Macroaxis News
Far too much social signal, news, headlines, and media speculation about Windtree Therapeutics that are available to investors today. That information is available publicly through Windtree media outlets and privately through word of mouth or via Windtree internal channels. However, regardless of the origin, that massive amount of Windtree data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Windtree Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Windtree Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Windtree Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Windtree Therapeutics alpha.

Windtree Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Huang James of 1112308 shares of Windtree Therapeutics at 0.1411 subject to Rule 16b-3
09/03/2024
2
Whats Going On With Windtree Therapeutics Stock Wednesday
09/04/2024
3
Windtree stock slides amid Phase 2b data for istaroxime
09/25/2024
4
Windtree Therapeutics to hold a virtual investor day - TipRanks
10/01/2024
5
Acquisition by Craig Fraser of 5431 shares of Windtree Therapeutics at 0.9099 subject to Rule 16b-3
10/08/2024
6
Windtree Therapeutics CEO buys 4.9k in company stock
10/09/2024
7
Disposition of 249004 shares by Bioengine Capital Inc. of Windtree Therapeutics at 12.15 subject to Rule 16b-3
10/18/2024
8
Short Interest in Windtree Therapeutics, Inc. Grows By 301.8
11/12/2024
9
ARMISTICE CAPITAL, LLC Acquires New Stake in Windtree Therapeutics Inc
11/15/2024
10
WINT Water Intelligence and Polygon enter partnership to deliver enhanced water damage prevention
11/21/2024

Additional Tools for Windtree Stock Analysis

When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.